The MedVi playbook.

What he actually did

Nothing here is secret. All of it is visible from the ads, the partner list and the price.

1. He sold the price gap, not the drug.Wegovy and Zepbound list above $1,000 a month. Compounded semaglutide at $149 to $179 is, to the customer, the same molecule at a sixth of the price. The product was never the injection. The product was the gap.
2. He rented everything that is regulated.OpenLoop Health and CareValidate supply the licensed physicians, the prescriptions, the pharmacies and the compliance. He owns the website, the ads and the customer. Every part that needs a licence belongs to somebody else.
3. One flat number, said in the ad.“$149 a month. No insurance. No waitlist. No hidden fees. Flat price forever.” We pulled 243 MEDVi-related ads from Meta’s ad library in June 2026. The figure $149 appears 406 times across them, and 162 of the ads share one headline word for word: “$149 a Month Tirzepatide Now Available!”
4. Volume on Meta, then let the winner run.Over 5,000 active ads under the MEDVi name at the peak. In our sample the median ad lived 36 days and the single best ran 127 days untouched. Three formats did the work: a hand holding the pen with the price baked into the picture, a “supplies are limited” overlay, and the confession opener, “You’ve tried. Nobody can say you haven’t.”
5. Faces, not the brand.222 of the 243 ads ran under pages named after a person rather than the company, and 203 of those under a single name. A face outperforms a logo in a feed. This is also the exact place the trouble started. See the bill.
6. An affiliate army with its own pages.“Wellness Access Center”, “Active Wellness Center”, “Modern Wellness”: separate pages, their own creative, $99 and $166 hooks, all pointing at tracking links on glp1.medvi.org. He paid for customers delivered, not for impressions bought.
7. AI as the staff.ChatGPT, Claude, Grok, Midjourney and Runway wrote the code, generated the ads and answered the customers. Two salaries at $401 million is not frugality. It is a different shape of company.

What it cost, so far

The three things that made it fast are the three things that made it fragile: rented compliance, borrowed faces, and a window.

• February 20, 2026. The FDA issued warning letter #721455 for misbranding. The site implied the products were FDA-approved and implied MEDVi was the compounder. Neither was true.
• The window was a shortage. Mass compounding of semaglutide was legal because the FDA listed the drug as in shortage. The FDA ended that listing in February 2025 (tirzepatide in December 2024). In March 2026 it sent warning letters to more than thirty telehealth companies in the same category at once.
• The faces were invented. Ads under fictitious personas with medical titles drew the press, letters from state attorneys general to Meta, and Meta’s own scrutiny of the account.
• January 2026. Partner OpenLoop Health disclosed a cybersecurity incident. Class actions followed. Renting compliance means renting the breach as well.
• March 2026. A security researcher found patient records reachable through sequential URLs with no login, reported to cover the full customer list at the time.
• A pending class action alleges the oral tirzepatide tablet has no viable absorption pathway. The cheapest product on the menu is the one in court.

He is still selling. The letter, the breach and the lawsuits have not closed the company. They have set the clock on it.

The parts that transfer

Strip the medicine out and seven things remain. Six of them are clean.

1. Find something people already want, priced out of reach, with a legal path that just opened.A shortage exemption, a rule change, a supplier that will now ship to anyone. The gap between the list price and your price is the whole business. You do not need a better product. You need to be first to the gap.
2. Rent the regulated part. Own the customer.Licences, prescriptions, insurance, banking rails, fulfilment. Pay a partner for each. Keep the domain, the ad account, the email list and the number that goes up.
3. One price. Put it in the headline.Flat, forever, no insurance, no waitlist, no hidden fees. Every one of those words removes a reason to wait. Do not make the customer click to find out what it costs.
4. Hundreds of variants, one metric, kill in a week, let winners run a quarter.The winner is not designed. It is found. Budget for the finding, and once it is found, stop touching it.
5. Real faces, your own.The persona shortcut is the one move that drew the letter. Use your face, your brother’s face, a customer who signed a release. The lift is the same. The letter is not.
6. AI for everything except the decisions.Code, creative, support, copy. Keep pricing, partners and what you promise the customer in a human’s hands, because that is what the regulator writes to.
7. Plan for the letter before you get it.A compliance read of every claim on the site. Certification before the first ad. Your own data on your own servers. A written answer to “what if the window shuts next quarter.” The playbook is fast because it skips these. You can be nearly as fast and keep them.

The code

• The product is the gap, not the thing.
• Rent what is regulated. Own who is paying.
• Say the price. Say it first.
• Volume finds the winner. Patience keeps it.
• Borrowed faces are borrowed time.
• Two people and the tools beat forty people and a deck.
• Every window closes. Be clean before it does.

He did not invent anything. He saw the gap first, said the price loudest, and rented everything that could get him in trouble. Two of those three are yours to copy.

Where every number comes from

• Forbes, April 2, 2026: How a telehealth startup found success with just $20,000 and AI.
• Dealroom: From $20K to $1.8B in revenue, summarising the New York Times profile of April 2, 2026.
• HealthDataConsortium: the FDA warning letter, the breach and the customer counts.
• Telehealth.org: FDA warns firms over compounded GLP-1 claims, March 2026.
• eMarketer: Fake doctor ads fuel scrutiny of GLP-1 marketer.
• Maryland Attorney General: letter to Meta on weight-loss advertisements.
• Forma’s own pull of 243 MEDVi-related ads from the Meta Ad Library, June 2026. Counts of headlines, prices, page names and run lengths above are from that sample, not from MEDVi.

Figures marked as reported come from the outlets above and have not been independently audited. MEDVi, Wegovy, Zepbound and all other marks belong to their owners. This page describes a business; it does not endorse selling compounded medication, and nothing here is medical, legal or financial advice.